Changes in Pituitary Iron and Volume With Deferasirox

Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01376622

Enrollment

130

Registered

2011-06-20

Start date

2008-11-30

Completion date

2011-07-01

Last updated

2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Overload

Brief summary

Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Currently on chronic transfusion therapy. * Duration of chronic transfusion \>1 year. * Age 2 to 25 years * On deferasirox monotherapy for the duration of the study. * Informed consent from legal guardian and/or patient. * On deferasirox for a minimum of 3 months at start of study.

Exclusion criteria

* Sickle cell disease or sickle-beta zero genotype. * Combination of deferasirox and another iron chelator.

Countries

United States

Outcome results